Financials
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
CARL Catalyst Timeline
Dated clinical, regulatory and corporate events for Carlsmed, Inc.
Past FDA Catalysts and PDUFA Decisions
How CARL actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Drug Pipeline Intelligence
No drug pipeline
Carlsmed, Inc. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every CARL program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Bertolini JeffreyOfficer (Chief Operating Officer) | Option | 747 23,236 held | $5.92 | 11/03/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in CARL
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PARKMAN HEALTHCARE PARTNERS LLC | 0.6 % (20 %) | 6.20 M | 597.32 K | 14.62% ( 76.19 K) |
Ownership Trends
CARL Short Interest
Shares sold short, counted twice a month.
Options Data
Option Volume
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
Competitive positioning
How CARL ranks across every disease it competes in
CARL News
Carlsmed to Participate in Upcoming Investor Conferences
Carlsmed, Inc. announced its participation in upcoming investor conferences. The company focuses on AI-enabled personalized spine surgery solutions. Webcasts for these events will be available on its investor website. Carlsmed aims to enhance healthcare outcomes while reducing costs in spine surgery.
Read more →Carlsmed® Reports Third Quarter 2026 Financial Results and Raises Full-Year Guidance
Carlsmed reported a strong third quarter for 2026, with revenue of $21.6 million, marking a 65% increase year-over-year. The company raised its full-year revenue guidance to between $78 million and $80 million. Key highlights include a significant growth in its surgeon user base and new reimbursement for its lumbar fusion procedure. However, the company also reported a net loss of $12.2 million.
Read more →Carlsmed, Inc. to Report Third Quarter 2026 Financial Results on November 10, 2026
Carlsmed, Inc. will report its third quarter 2026 financial results on November 10, 2026. The announcement includes a conference call and webcast scheduled for 1:30 PM Pacific Time. The company focuses on AI-enabled personalized spine surgery solutions to enhance healthcare outcomes.
Read more →Carlsmed Launches aprevo® Lumbar Bi-lateral Posterior System
Carlsmed, Inc. has launched its aprevo® Lumbar Bi-lateral Posterior System at the NASS Annual Meeting. This system expands Carlsmed's technology platform, enabling a personalized approach to spine fusion. Surgeons have reported positive outcomes and increased patient specificity with the system. The technology utilizes AI to create tailored surgical plans.
Read more →Carlsmed, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Carlsmed, Inc. has granted stock options and restricted stock units to its new CFO and Chief Product and AI Officer as part of their employment inducements. The grants, approved by the Compensation Committee, aim to align the interests of the new executives with the company's long-term goals. The stock options and RSUs will vest over several years, promoting retention.
Read more →Carlsmed Appoints Tony Jarc as Chief Product and AI Officer
Carlsmed has appointed Tony Jarc, Ph.D., as Chief Product and AI Officer to lead the development of its next-generation technology platform for personalized spine surgery. This strategic move comes as the company aims to scale its innovations and improve patient outcomes. Jarc's extensive experience in AI and digital products is expected to bolster Carlsmed's market leadership.
Read more →Carlsmed Appoints Richard Heppenstall as Chief Financial Officer
Carlsmed has appointed Richard Heppenstall as its new Chief Financial Officer, succeeding Leo Greenstein. Heppenstall brings nearly 30 years of experience in finance and operations within healthcare and technology. The company reaffirms its revenue guidance for 2026, projecting a 50% growth over the previous year, supported by new product launches and reimbursement policies.
Read more →Carlsmed, Inc. Files Patent Infringement Lawsuit against DeGen Medical
Carlsmed, Inc. has filed a patent infringement lawsuit against DeGen Medical in the U.S. District Court for South Carolina. The lawsuit claims that DeGen is infringing on eight of Carlsmed's patents related to spine surgery technology. Carlsmed seeks injunctive relief and damages, emphasizing its dedication to advancing spine surgery standards.
Read more →Carlsmed, Inc. Announces Chief Operating Officer Appointment
Carlsmed, Inc. has announced the promotion of Jeff Bertolini to Chief Operating Officer, effective immediately. Bertolini, who joined the company in 2024, has previously held senior roles in operations and technology. His leadership is expected to enhance Carlsmed's capabilities in personalized spine surgery solutions, aligning with the company's mission to improve healthcare outcomes.
Read more →Carlsmed® Reports Second Quarter 2026 Financial Results and Raises Full-Year Guidance
Carlsmed, Inc. reported a strong second quarter for 2026 with revenues of $18.9 million, marking a 57% increase from the previous year. The company raised its full-year revenue guidance to between $74 million and $78 million, driven by robust growth in its AI-enabled spine surgery solutions. Notably, surgeon adoption has surged, and a recent CMS ruling is expected to further enhance reimbursement for their procedures.
Read more →Carlsmed Announces Favorable Reimbursement for aprevo® lumbar Procedures
Carlsmed, Inc. announced that the Centers for Medicare & Medicaid Services (CMS) has finalized a favorable reimbursement policy for aprevo® lumbar spinal fusion procedures. This decision, effective October 1, 2026, includes new MS-DRG assignments that will enhance hospital and patient access to the procedure. The CEO highlighted the importance of this policy in improving healthcare outcomes and reducing costs.
Read more →Carlsmed, Inc. To Participate in Upcoming Investor Conferences
Carlsmed, Inc. has announced its participation in two upcoming investor conferences. The company will host one-on-one meetings at the 11th Annual Needham Virtual MedTech & Diagnostics Conference on August 10, 2026, and will participate in a fireside chat at the Bank of America SMID Cap Virtual Conference on August 12, 2026. These events highlight Carlsmed's commitment to engaging with investors and showcasing its AI-enabled personalized spine surgery solutions.
Read more →Carlsmed Inc. to Report Second Quarter 2026 Financial Results on August 5, 2026
Carlsmed, Inc. announced it will release its second quarter 2026 financial results on August 5, 2026. The company, known for its AI-enabled personalized spine surgery solutions, will host a conference call and webcast to discuss the results. This event reflects the company's commitment to transparency with its investors.
Read more →Carlsmed® Reports First Quarter 2026 Financial Results
Carlsmed, Inc. reported a strong first quarter for 2026, achieving $16.1 million in revenue, a 58% increase from the previous year. The company raised its full-year revenue guidance to between $72 million and $77 million. Notably, clinical data published in the Global Spine Journal highlighted a significant reduction in revision rates for its product, aprevo®. The company is optimistic about its upcoming product launches and continued growth.
Read more →Carlsmed, Inc. To Participate in Upcoming Investor Conferences - April 28, 2026
Carlsmed, Inc. has announced that CEO Mike Cordonnier will participate in upcoming investor conferences. The company aims to improve healthcare outcomes through AI-enabled personalized spine surgery solutions. Live and archived webcasts of the presentations will be accessible on their investor relations website.
Read more →Carlsmed Inc. to Report First Quarter 2026 Financial Results on May 5, 2026
Carlsmed, Inc. has announced that it will report its first quarter 2026 financial results on May 5, 2026, after market close. The company will also host a conference call and webcast at 1:30 PM Pacific Time to discuss the results. This event reflects Carlsmed's commitment to transparency and investor engagement.
Read more →Carlsmed® Reports Fourth Quarter and Full Year 2025 Financial Results
Carlsmed, Inc. reported strong financial results for Q4 and full year 2025, with revenues of $15.2 million and $50.5 million respectively, reflecting year-over-year growth of 61% and 86%. The company achieved a gross margin of 76.5% and improved operational efficiency by reducing lead times. The CEO highlighted significant advancements in patient outcomes through their AI-enabled spine surgery solutions.
Read more →Carlsmed, Inc. To Participate in the 2026 Canaccord Genuity Musculoskeletal Conference
Carlsmed, Inc. announced its participation in the 2026 Canaccord Genuity Musculoskeletal Conference, where CEO Mike Cordonnier will present on March 2, 2026. The conference will take place in New Orleans, LA, and a live webcast will be available for registered participants. This event highlights Carlsmed's commitment to advancing spine surgery through AI technology.
Read more →Carlsmed Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026
Carlsmed, Inc. has announced it will report its fourth quarter and full year 2025 financial results on February 25, 2026. The company, known for its AI-enabled personalized spine surgery solutions, will host a conference call and webcast at 1:30 PM Pacific Time on the same day. This event demonstrates the company's commitment to transparency with its investors.
Read more →